Living with a pacemaker: patient-reported outcome of a pacemaker system

Peter Magnusson1,2* and Per Liv2

Abstract

Background: The aim of this study was to assess among pacemaker patients their overall satisfaction with the pacemaker system, pain, soreness/discomfort, cosmetic results, restrictions due to impaired movement of the shoulder/arm/chest, related sleep disturbances, and concern about possible device malfunction.

Methods: The seven-item questionnaire was mailed to patients from a single center who had a pacemaker implant or replacement between 2006 and 2016. A higher score indicated worse outcome on a visual analog scale (VAS) of 0–100 mm.

Results: The response rate was 75.5% and 342 questionnaires were analyzed. Median age of respondents was 77.6 years and 57.0% were males. In total, 65 complications requiring surgery (10 pocket corrections (2.9%), 5 in females) occurred during a median follow-up of 5.6 years. The distribution of the primary outcome had a median score of 5 while the 75th percentile was 13. Cosmetic appearance was significantly associated with reoperation (but not other variables). Overall scores for men and women were 5 vs. 6, respectively, which achieved significance (p = 0.042). Median ratings of pain, soreness/discomfort, cosmetic appearance, range of motion, sleep, and concern about device malfunction were all ≤5. Females reported worse outcomes for all questions, except for cosmetic results and concern about malfunction.

Conclusions: The vast majority of patients report excellent overall satisfaction with the pacemaker system, and are not affected by pain, soreness/discomfort, or concern about device malfunction. They also reported favourable outcomes with respect to cosmetic results, shoulder movement, and sleep. However, some patients underwent a surgical correction of the pacemaker pocket.

Keywords: Arrhythmia, Complication, Experience, Pacemaker, Pocket

Background

A permanent pacemaker is indicated in patients with bradycardia, i.e. second- or third-degree atrioventricular block, significant sinus node dysfunction, tachycardia-bradycardia syndrome, bundle branch block with a history of syncope, and, in specific circumstances, in various disease states, according to guidelines [1]. In symptomatic patients with heart failure, with an ejection fraction ≤40% and bundle branch block despite optimal medical therapy, cardiac resynchronization therapy (CRT) is indicated [1]. The implantation incidence in Western Europe is 938 bradycardia pacemakers and 140 CRT devices per million annually [2].

A transvenous pacemaker system consists of one (VVI or AAI) or two leads (DDD) fixated in the right side of the heart; a CRT devices adds a special lead on the left side. The lead(s) is plugged into a pacemaker device (50 × 50 mm and 5-7 mm thick and weight 20-30 g), which is inserted beneath the collarbone, typically on the left side. Perioperative complications can occur during vascular access (pneumothorax, arterial puncture, and nerve plexus injury) and during lead fixation in the myocardial wall (perforation, tricuspid valve damage, and sustained arrhythmias) [3, 4]. Postoperative and long-term complications requiring surgical revision include infections, lead malfunction due to oversensing or mechanical failure, technical device failure, and discomfort with the device system [5]. In many countries, these complications are reported in a national register e.g. the...
Swedish Pacemaker Registry and the Danish Pacemaker Register [6, 7]. In a validation study of the latter registry, 9.5% of cardiac implantable device patients were affected by complications after half a year [8]. However, the patient-reported experience, specifically with regard to the pacemaker system, is not completely understood [9]. Furthermore, generic questionnaires on health-related quality of life lack disease specificity [10]. Therefore we developed a questionnaire to assess overall satisfaction with the pacemaker system (primary outcome), and to assess secondary outcomes of pain, soreness/discomfort, cosmetic results, restrictions of movement impairment of the shoulder/arm/chest, sleep disturbances related to the pacemaker generator, and concern about device malfunction. We aimed to address these research questions in a cross-sectional cohort study in an unselected population of pacemaker patients with various duration since first implantation.

Methods

Setting
The records of all patients ≥18 years who received an initial pacemaker or a replacement pacemaker at Gävle Hospital, Region Gävleborg between December 2006 and December 2016 were extracted from the electronic system Provisio™.

We excluded patients with a history of primary a CRT implant and/or an implantable defibrillator. We used search codes FPE00, FPE10, FPE20, and FPE40 according to the International Code of Disease and Classification [11], which have not changed during the study period.

Data collection and power analysis
The search yielded 2950 patients. A power analysis was performed using Monte-Carlo simulations from a hypothetical outcome of the primary outcome: log-normal distribution, truncated at 10 mm with a log-scale mean score of 1.6 and a log-scale standard deviation of 1. The simulations showed that 400 patients would be sufficient to estimate the median VAS score of with an expected 95% confidence interval width of 7 mm, as estimated from BCa non-parametric bootstrapping. This was deemed to be a sufficient precision.

To compensate for non-responses, one fifth of the patients (590 out of 2950) were randomly selected using a computer script written in R and manually entered into the daily updated census register to ensure that we included only living patients [12]. After removal of duplicates, the final sample consisted of 453 patients, who were mailed the questionnaire.

In early January of 2017, the questionnaire was sent by regular mail together with information about the study, an informed consent form, and a return envelope. A reminder was sent 6 weeks later and a final reminder another 6–8 weeks thereafter. A phone call preceded the last reminder. In addition, a phone call was made to patients who returned incomplete questionnaires.

The questionnaire
The questionnaire consisted of seven questions, to be answered on a 100 mm visual analog scale (VAS) with wording and pictures at each end (see example Fig. 1). A higher score indicates worse outcome.

The questions appear below with the words at either extreme on the VAS shown in parentheses.

1. How satisfied are you overall with your pacemaker? (Very satisfied, Very dissatisfied).
2. How much pain related to your pacemaker do you experience? (No pain, Considerable pain).
3. How much are you bothered by soreness/discomfort from the pacemaker? (No soreness/discomfort, Considerable soreness/discomfort).
4. How do you feel about the cosmetic appearance of your pacemaker? (Very Good, Very bad).
5. Do you experience any restrictions of movement of shoulder/arm/chest related to your pacemaker? (No restriction of movement, Considerable restriction of movement).
6. How would you rate any sleep disturbances related to your pacemaker generator? (No sleep disturbance, Considerable sleep disturbance).
7. How much concern do you feel that your pacemaker will stop working or malfunction? (No concern, Always concerned).

The questionnaire was developed by the authors and face validity was addressed by input from physicians and nurses involved in the follow-up of pacemaker patients. Laypeople were consulted to assure that the form was clearly understood and easy to follow. As generic quality-of-life instruments could not capture the specific patient-reported outcomes this paper aimed to address and as no suitable disease-specific instrument could be found in the literature, we developed a new questionnaire based on clinical experience. This new questionnaire has not been evaluated with regards to reliability or validity, which we recognize as a limitation.

---

Fig. 1 Question 1 in the questionnaire. A higher score indicates worse outcome.
Other variables
In addition to the questionnaire, we asked patients to fill in their current medications, which were categorized as follows: sleeping pills (zolpidem, propiomazin) including other benzodiazepines, acetaminophen (paracetamol), selective serotonin reuptake inhibitors, opioids, and corticosteroids. Complications were defined as those requiring surgery involving the pacemaker system, i.e. opening of the pacemaker pocket. Information on complications was obtained from medical records and registry data.

Statistics
Numeric data were described as frequencies, percentages, medians (interquartile range [IQR]), means (standard deviation [SD]), and percentiles. All VAS-scores on the questionnaire were reported in millimeters (mm). Tests of differences in VAS results between subgroups were performed using the Mann-Whitney U-test. Associations between continuous variables were assessed using Spearman’s correlation coefficient. Possible differences in proportion of response rates between males and females were tested using Fisher’s exact test. The choice of using non-parametric statistics was made based on non-normality of all measured variables, as seen from graphically examination of data. All statistical tests were two-sided with a significance level of 0.05. The database in Excel 2010 (Microsoft Corporation, Redmond, WA) was imported for analyses using R (R Core Team, 2015).

Ethics
The Regional Ethical Committee in Uppsala approved the study (protocol number 2016/478).

Results
A total of 342 questionnaires were analyzed. Ages ranged from 30 to 100 years, with a median age of 77.6 years (interquartile range [IQR]: 70–84) and the mean age was 75.9 years (standard deviation [SD] 12.0). There were more males (n = 195; 57.0%) than females (n = 147; 43%). Patients had DDD (76.6%), single-chamber (17.0%), or CRT (6.4%) pacemakers. During the median time since primary pacemaker implant of 5.6 years (mean 6.5 years, SD 5.1), 65 complications requiring surgical intervention occurred, mainly lead-related malfunction or perforation. One patient had two complications. Notably, 10 patients (2.9%), of whom 5 were females, underwent pacemaker pocket revision, i.e. a correction. Median time since last device surgery was 4.3 years (IQR 1.73–8.1 years). In our study, over a median time since primary implant of 5.6 years, patients underwent device replacement either before battery depletion (n = 104, 30.4%) or due to complications (n = 51, 14.9%). The pharmacological regimens that could influence the patient’s pacemaker experience were mainly sleeping pills including benzodiazepines (n = 28; 7.3%), acetaminophen (paracetamol) (n = 18; 5.3%), selective serotonin reuptake inhibitors (n = 18; 5.3%), opioids (n = 8; 2.3%), and corticosteroids (n = 4; 1.2%). More than half of the patients (59.4%) were overweight (body mass index [BMI] > 25) at the time they completed the questionnaire. Median BMI was 26.0 kg/m² (IQR 24.6–29.3) and only 3.3% reported BMI < 20 kg/m². Patient characteristics are summarized in Table 1.

Analysis of non-response
The response rate of the questionnaire was 75.5%. Reasons for non-response were as follows: dementia (n = 10), no registered postal address/emigration (n = 6), or unknown (n = 95). Fisher’s exact test revealed no stastically significant difference in response rate with regard to sex; 78.0% among males returned the questionnaire and females 72.4% (p = 0.188). Non-responders were significantly older than responders (median age: 82.4 years vs 77.6 years, p = 0.018).

Table 1 Characteristics of 342 pacemaker patients

| Variable                      | n  |
|-------------------------------|----|
| Number of patients            | 342|
| Median age (years)            | 77.6 (IQR 70.4–84.2) |
| Males                         | 195 (57.0%) |
| Pacemaker type                |     |
| DDD                           | 262 (76.6%) |
| VVI                           | 51 (14.9%) |
| AAI                           | 7 (2%) |
| CRT-P                         | 22 (6.4%) |
| Number of procedures          |     |
| 1                             | 229 (67.0%) |
| 2                             | 67 (19.6%) |
| 3                             | 29 (8.5%) |
| 4                             | 15 (4.4%) |
| 5                             | 1 (0.3%) |
| 6                             | 1 (0.3%) |
| Complications requiring reintervention |     |
| Lead malfunction              | 40 (11.7%) |
| Pocket correction             | 10 (2.9%) |
| Perforation                   | 5 (1.5%) |
| Extraction                    | 9 (2.6%) |
| Exploration unipolar lead     | 1 (0.3%) |
| Body-mass index (kg/m²)       |     |
| < 20                          | 11 (3.3%) |
| 20–25                         | 119 (35.7%) |
| 25–30                         | 130 (39%) |
| > 30                          | 73 (21.9%) |
Primary outcome
As for the ratings of each seven questions, the distribution of the primary outcome overall satisfaction was heavily skewed to the right (Fig. 2). Median score was 5 while the 75th percentile was 13 and the 95th percentile 44.9.

Men and women had similar median scores (5 vs. 6, respectively) but the Mann-Whitney U test revealed statistical significance ($p = 0.042$) driven by differences in the higher percentiles (75th percentile: 15.5 vs 11.5; 95th percentile: 54.2 vs 30.3). Patients who underwent reoperation did not report a significantly different outcome in overall satisfaction compared to those who did not undergo a revision ($p = 0.14$).

Secondary outcomes
Median ratings of pain, soreness/discomfort, cosmetic results, movement, sleep, and concern about device malfunction were all ≤5. The 75th percentiles ranged from 8 (pain) to 16 (cosmetic results) and the 95th percentile ranged from 38 (pain) to 54 (movement), see Tables 2 and 3. Statistically significant differences between males and females were found for all questions, except for cosmetic results and concern about device malfunction. Reoperation was significantly associated with worse outcome for cosmetic results, but not for the other variables.

Correlations
None of the seven outcome scores correlated significantly to patient age at the time of evaluation (Spearman’s rho ranging between 0.00 and 0.16, all $p$-values ≥0.355), time since the first implantation (Spearman’s rho between -0.09 and -0.01, all $p > 0.12$) or BMI (Spearman’s rho between -0.10 and 0.00, all $p > 0.48$). However, a longer time since last pacemaker surgery was significantly correlated to better outcomes for all questions (overall satisfaction $\rho = -0.26$, $p < 0.001$; pain
Magnusson and Liv BMC Cardiovascular Disorders (2018) 18:110
Page 5 of 7

Table 2 Percentile distribution and mean values (standard deviations) of responses on VAS-scale (mm)

| Question                  | 5%   | 25%  | 50%  | 75%  | 95%  | Mean (SD) |
|---------------------------|------|------|------|------|------|-----------|
| Overall satisfaction      | 0    | 2    | 5    | 13   | 44.9 | 10.3 (14.1)|
| Pain                      | 0    | 1    | 3    | 8    | 38   | 8.3 (13.1)|
| Soreness/discomfort       | 0    | 2    | 4    | 14   | 62   | 13 (19.5)|
| Cosmetic results          | 0    | 2    | 5    | 15.8 | 50.9 | 12.4 (17.9)|
| Movement                  | 0    | 1    | 4    | 10   | 53.9 | 10.3 (17.8)|
| Sleep                     | 0    | 2    | 4    | 9    | 44.8 | 9.2 (14.8)|
| Concern about malfunction | 0    | 2    | 4    | 13   | 52.9 | 11.7 (18.4)|

**Table 3** Median and interquartile range (IQR) with regard to sex and reoperation (p-value using Mann-Whitney U-test)

| Question                  | Females, median (IQR) | Males, median (IQR) | p-value | No reop, median (IQR) | Reoperation, median (IQR) | p-value |
|---------------------------|-----------------------|---------------------|---------|-----------------------|-------------------------|---------|
| Overall satisfaction      | 6 (3–15.5)            | 5 (2–11.5)          | 0.042   | 6 (2–14)              | 4 (2–11)                | 0.142   |
| Pain                      | 4 (2–11)              | 3 (1–7)             | 0.025   | 3 (2–9)               | 3 (1–8)                 | 0.612   |
| Soreness/discomfort       | 6 (2–20)              | 4 (1–11)            | 0.002   | 4 (2–14)              | 5 (2–15)                | 0.568   |
| Cosmetic results          | 5 (2–17)              | 4 (2–14)            | 0.201   | 4 (2–13)              | 7 (2–21)                | 0.043   |
| Movement                  | 4 (2–13)              | 3 (1–8)             | 0.079   | 4 (1–10)              | 3 (1–8)                 | 0.958   |
| Sleep                     | 5 (2–11.5)            | 3 (1–7)             | 0.009   | 4 (2–8)               | 3 (1–9)                 | 0.595   |
| Concern about malfunction | 5 (2–13.5)            | 4 (1–12)            | 0.12    | 5 (2–13)              | 3 (2–11)                | 0.253   |

Females more often report pain, soreness/discomfort, and sleep disturbances

We found statistically significant differences in reported overall satisfaction, pain soreness/discomfort and sleep between the sexes, where females more frequently reported worse outcome than males. Since females are generally smaller, the device may more readily impede arm movement. Interestingly, there were few patients who reported cosmetic problems and there was no difference between males and females in the assessment of cosmetic results. Although the study population was 57% men, among the patients who underwent surgical revision to correct pacemaker position in the pocket, 50% were women (n = 5).

Age, BMI, reoperation

Interestingly, neither age nor BMI seemed to affect the patient-reported outcomes for our survey. The fact that re-operation was not associated with worse outcome is reassuring, but it still must be remembered that surgical revision increases the risk of infection and may require lead extraction. From the perspective of each individual patient, it is important to take every measure to avoid reoperation due to complications and consider the optimal technique for pacemaker and lead placement at the initial implantation [17, 18].

Future perspectives

This study provides insights into the perceptions of pacemaker patients about their device therapy. Despite the increasing proportion of home-monitoring devices, which have improved patient safety and clinical logistics, it is still important to evaluate outcomes from a holistic and pacemaker-patient-centric viewpoint. The creation of the pocket during the initial implantation is crucial. There is an ongoing trial designed to address whether intramuscular implantation is superior to a subcutaneous pocket for initial pacemaker placement [19].

The introduction of a new leadless pacemaker (Micra™) may eliminate problems due to the pocket and leads. However, this device has limited availability, few indications, and may be cost prohibitive [20, 21]. Rechargeable
pacemakers seem to offer the theoretical advantages of reducing device replacements, but there are no rechargeable devices currently on the market.

**Strengths and weaknesses**

This study evaluates pacemaker therapy from the patient perspective, going beyond data in registries in order to address patient attitudes without the potential bias that could be introduced by interviewing patients during clinical follow-up. Many of our respondents were elderly and some suffered cognitive impairments and were not able to follow instructions, even though the questionnaire was short and straightforward. Nonresponders tended to be older than respondents, but males and females participated in the study to the same extent. In order to overcome the limitations of a cross-sectional study design, repeated outcome assessments at predefined follow-up periods are required. Psychological coping strategies, like adaptation, were not addressed. Finally, we would like to point out that multiple statistical tests were performed in our study, but no correction for mass significance has been made, which means that caution is warranted when interpreting individual tests. An alternative approach would have to perform such corrections to reduce the risk of statistical type 1-errors, but at the cost of an increased risk of type 2-errors.

**Conclusion**

The vast majority of pacemaker patients report excellent overall satisfaction with their pacemaker system, including the absence of pain, no soreness/discomfort, acceptable cosmetic results, good shoulder movement, sound sleep, and no concerns about device malfunction. In 2.9% of the study population, a surgical procedure was needed to correct device placement. Females report worse overall satisfaction, pain, soreness/discomfort, and more sleep problems related to the pacemaker.

**Abbreviations**

BMI: body mass index; CRT: cardiac resynchronization therapy; IQR: interquartile range; SD: standard deviation; VAS: visual analog scale

**Acknowledgements**

The authors acknowledge editing by Jo Ann LeQuang of LeQ Medical who reviewed the manuscript for American English use. Thanks to Julia Fahlstedt and Thesee Martinell for administrative support.

**Funding**

Region Gävleborg funded this research project.

**Availability of data and materials**

The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

**Authors’ contributions**

PM: project idea, design, data collection and analysis, major writing of the manuscript, project management. PL: design with regard to statistical issues, data collection and analysis, critical revision of the manuscript. Both authors approved the manuscript for submission.

**Ethics approval and consent to participate**

The study was approved by the Regional Ethical committee in Uppsala (Dnr 2015/060). All patients gave their written consent to participate in the study.

**Competing interests**

The authors declare that they have no competing interests.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Received: 21 June 2017 Accepted: 24 May 2018 Published online: 04 June 2018**

**References**

1. Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Botani G, Breithardt OA, Cleland J, et al. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European heart rhythm association (EHRA). Europace. 2013;15:1070–118.
2. www.eucomed.org/medical-technology/facts-figures
3. Ellenbogen KA, Hellkamp AS, Wilkoff BL, Camm AJ, Hadijs TA, Lee KL, et al. Complications arising after implantation of DDD pacemakers: the MOST experience. Am J Cardiol. 2003;92:740–1.
4. Udo EO, Zulthoff NP, van Hemel NM, de Cock CC, Hendriks T, Doevendans PA, Moons KG. Incidence and predictors of short- and long-term complications in pacemaker therapy: the FOLLOWPACE study. Heart Rhythm. 2012;9:278–35.
5. Eberhardt F, Bode F, Bonnemeier H, Boguszewski F, Schlei M, Peters W, Wiegard UK. Long term complications in single and dual chamber pacing are influenced by surgical experience and patient morbidity. Heart. 2005;91:500–6.
6. Gadler F, Valzania C, Linde C. Current use of implantable electrical devices in Sweden: data from the Swedish pacemaker and implantable cardioverter-defibrillator registry. Europace. 2015;17:669–77.
7. https://ssl.icddata.dk/download/Danish_Pacemaker_and_ICD_Register__Annual_Report_2015b.pdf
8. Kirkfeldt RE, Johansen JB, Noehr EA, Jorgensen OD, Nielsen JC. Complications after cardiac implantable electronic device implantations: an analysis of a complete, nationwide cohort in Denmark. Eur Heart J. 2014;35:1186–94.
9. Udo EO, van Hemel NM, Zulthoff NP, Nijboer H, Takis W, Doevendans PA, Moons KG. Long term quality-of-life in patients with bradycardia pacemaker implantation. Int J Cardiol. 2013;168:2159–63.
10. Stofmeel MA, Post MW, Kelder JC, Gribbee DE, van Hemel NM. Quality-of-life of pacemaker patients: a reappraisal of current instruments. Pacing Clin Electrophysiol. 2000;23:946–52.
11. World Health Organization. International Classification of Diseases (ICD)”. Retrieved 2017.
12. Statistics Sweden Database. Official population statistics. 2015. www.scb.se/cen/ BEO1
13. Buch E, Boyle NG, Belzott PH. Pacemaker and defibrillator lead extraction. Circulation. 2011;123:378–80.
14. Johansen JB, Jorgensen OD, Moller M, Arnsbo P, Mortensen PT, Nielsen JC, et al. Infection after pacemaker implantation: infection rates and risk factors associated with infection in a population-based cohort study of 46299 consecutive patients. Eur Hear J. 2011;32:991–8.
15. Kirkfeldt RE, Johansen JB, Noehr EA, Moller M, Arnsbo P, Nielsen JC, et al. Risk factors for lead complications in cardiac pacing: a population-based cohort study of 28,860 Danish patients. Heart Rhythm. 2011;8:1622–8.
16. Tobin K, Stewart J, Westveer DF, Fruhnin H. Acute complications of permanent pacemaker implantation: their financial implication and relation to volume and operator experience. Am J Cardiol. 2003;92:774–6.
17. Rajappan K. Permanent pacemaker implantation technique: part I. arrhythmias. Heart. 2009;95:259–64.
18. Rajappan K. Permanent pacemaker implantation technique: part II. Heart. 2009;95:334–42.
19. Magnusson P, Wennström L, Kastberg R, Liv P. Placement of cardiac Pacemaker trial (POCKET) – rationale and design: a randomized controlled trial. Heart Int. 2017;12(1):e8–e11.
20. Reynolds DW, Duray GZ, Omar R, Soejima K, Neuzil P, Zhang S, Narasimhan C, et al. A leadless Intracardiac Transcatheter pacing system. N Engl J Med. 2016;374(6):533–41.

21. Duray GZ, Ritter P, El-Chami M, Narasimhan C, Omar R, Tolosana JM, Zhang S, et al. Micra Transcatheter pacing study group. Long-term performance of a transcatheter pacing system: 12-month results from the Micra Transcatheter pacing study. Heart Rhythm. 2017;14(5):702–9.